1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Cancer Genetic and Genomic Testing Health Equity Fund" is currently closed and not accepting applications.
Cancer Genetic and Genomic Testing Health Equity Fund is sponsored by Co-Pay Relief. This fund covers the cost of physician-prescribed genetic and genomic tests for cancer, including tests to determine cancer risk based on heredity and genomic testing for diagnosis, mutation identification, treatment selection, and monitoring cancer growth.
Get alerted about grants like this
Get emailed when new opportunities from “Co-Pay Relief” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
TotalAssist financial assistance for healthcare costs Get notified when your fund opens Nonprofit patient partners How TotalAssist helps you How financial assistance works What are health equity funds?
Getting started after approval Información en español sobre TotalAssist Approval & getting started For patients, pharmacies, and providers Nonprofit Patient Partner Portal Quick check: application and claim status Patient Advocate Foundation How to support TotalAssist Our contact center will be closed on Friday, July 3, 2026, in observance of Independence Day. Apply online and manage your grants 24/7 in your portal account.
Use our quick action tools to check grant and claims information, activate a travel card, and more. Portal login and quick tools Portal login for nonprofits Get help with your out-of-pocket healthcare costs TotalAssist is the nation’s most comprehensive charitable patient financial assistance program—covering nearly 150 serious and chronic conditions. Check your eligibility and apply for a TotalAssist grant today.
Quick eligibility checker Answer a few short questions to find out if you might be eligible for a TotalAssist fund.
No documents or personal information needed Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML) Alzheimer’s disease health equity Ankylosing spondylitis (AS) Basal cell carcinoma (BCC) Biliary tract cancer (BTC) Breast cancer health equity Cancer genetic and genomic testing Chronic inflammatory demyelinating polyneuropathy (CIDP) Chronic kidney disease (CKD) Chronic lymphocytic leukemia (CLL) Chronic obstructive pulmonary disease (COPD) Chronic obstructive pulmonary disease (COPD) health equity Chronic spontaneous urticaria (CSU) Coronary artery disease (CAD) health equity Cushing’s disease or syndrome Diabetic macular edema (DME) Diabetic retinopathy (DR) Diffuse large B-cell lymphoma (DLBCL) Duchenne muscular dystrophy (DMD) Eosinophilic granulomatosis with polyangiitis (EGPA) Fabry disease health equity Gastrointestinal stromal tumors (GIST) Gaucher disease health equity Glioblastoma multiforme (GBM) Graft vs host disease (GvHD) Growth hormone deficiency Heart failure (HF) health equity Hemolytic uremic syndrome (HUS) Hepatitis B (HepB) health equity Hepatitis C (HepC) health equity HIV, AIDS, and prevention HIV, AIDS, and prevention health equity Hypertrophic cardiomyopathy Immune thrombocytopenic purpura (ITP) Inflammatory bowel disease (IBD) Inherited retinal disease (IRD) Long-chain fatty acid oxidation disorders (LC-FAOD) Lupus (SLE) health equity Lysosomal acid lipase deficiency (LAL-D) Macular degeneration and related diseases Mantle cell lymphoma (MCL) Metabolic dysfunction-associated steatohepatitis (MASH) Metastatic colorectal cancer Metastatic colorectal cancer health equity Metastatic gastric cancer Metastatic prostate cancer Mucopolysaccharidosis type III (MPS III) Mucopolysaccharidosis type VII (MPS VII) Mucopolysaccharidosis type VII (MPS VII) health equity Multiple myeloma health equity Multiple sclerosis (MS) health equity Myelodysplastic syndromes (MDS) Neuromyelitis optica spectrum disorder (NMOSD) Neurotrophic keratitis (NK) Non-Hodgkin’s lymphoma (NHL) Non-small cell lung cancer (NSCLC) Non-small cell lung cancer (NSCLC) health equity Ovarian cancer health equity Parkinson’s disease health equity Paroxysmal nocturnal hemoglobinuria (PNH) Peripheral vascular and artery disease Philadelphia chromosome negative myeloproliferative neoplasms (MPN) Pompe disease health equity Primary biliary cholangitis (PBC) Prostate cancer health equity Psoriatic arthritis (PsA) Renal cell carcinoma (RCC) Retinal vein occlusion (RVO) Rheumatoid arthritis (RA) Short bowel syndrome (SBS) Small cell lung cancer (SCLC) Social needs assessment & intervention Solid organ transplant preservation and rejection prevention Spinal muscular atrophy (SMA) Spinal muscular atrophy (SMA) health equity Thyroid eye disease (TED) Type 2 diabetes (T2DM) health equity Uterine cancer health equity Virology testing health equity Von Willebrand disease (vWD) Waldenstrom macroglobulinemia Please select a fund to continue.
Please confirm you are in treatment for this condition by a healthcare provider in the U.S. or U.S. territories. Find your medication or treatment: Please select a medication to continue. Do you have [health insurance; government-insured health coverage] that covers the medication or treatment?
If you do not have this coverage, you might not be eligible for this fund. State or territory where you reside: Please select your state. Please enter a valid 5-digit ZIP code.
Estimated current annual income: $ Please enter your estimated annual income. TotalAssist helps you focus on your care Patient Advocate Foundation’s TotalAssist program helps you afford eligible out-of-pocket healthcare costs including medication copays, coinsurance and deductibles, health insurance premiums, office visit charges the day of treatment, and administration charges related to treatment.
Grants are yours to use how you see fit for eligible expenses, so affording care is one less thing to worry about. Learn how TotalAssist helps you Getting help is easy and quick Search by disease or medication name and check your eligibility. If you’re eligible, apply today!
Find out instantly if you’re approved. Get started with our helpful guides Questions about grants and claims? Find answers in our help center about TotalAssist grants, including the application process, submitting claims, using your portal account, and more.
Chat live online or call us at 866-512-3861, Monday through Friday, 8:30am to 5:30pm ET. You can also ask for an interpreter in your preferred language. Quickly check grant and claim status No login or registration needed!
Check your grant balance, award amount, claim status, and other useful information using our quick check tool. Check application status, grant balance, claim status, and more. Your support has given me the opportunity to take the drug to help slow down the progression of my disease.
I could not do this without your support! Thank you!
Steven, living with pulmonary hypertension Our real impact in the lives of patients patients helped nationwide provided in financial assistance funds for serious and chronic illnesses helping patients access and afford care—and stay on treatment Updates for FundFinder users: continued service with enhanced options Patient Advocate Foundation lanza TotalAssist, el programa benéfico de asistencia financiera para pacientes más grande y completo del país Patient Advocate Foundation launches TotalAssist, nation’s largest and most comprehensive charitable patient assistance program Search by disease or medication name to find your fund, check eligibility, and apply today.
Find answers in our help center about eligibility, applying, claims, portal accounts, and more. Connect with a support specialist Mon – Fri, 8:30am – 5:30pm ET by chat, or call 866-512-3861.
According to the current listing, eligibility includes: Patients with household income 500% or less of Federal Poverty Guideline (adjusted for COLI and household size), all insurance types, and must reside in an eligible county and receive treatment in the United States. Confirm the full requirements in the official notice before applying.
The published deadline was July 1, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Cancer Genetic and Genomic Testing Health Equity Fund is funded by Co-Pay Relief. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Diabetic Retinopathy (Co-Pay Relief Program) is sponsored by Co-Pay Relief. This fund, while currently closed, will reopen as TotalAssist on July 1, 2026, and will offer disease-specific financial assistance for diabetic retinopathy. It provides co-pay, co-insurance, deductibles, office visit and administration charges, and medical insurance premium assistance for eligible patients. While not a research grant, it directly supports individuals affected by diabetic retinopathy by alleviating financial burdens related to treatment.
Diabetic Macular Edema (DME) Fund is sponsored by Patient Advocate Foundation Co-Pay Relief (CPR). This fund provides financial assistance for co-pay, co-insurance, and deductibles, as well as office visits and administration charges related to treatment for Diabetic Macular Edema. While primarily for patients, university-affiliated clinics may assist patients in applying.
Discovery of the Genetic Basis of Childhood Cancers and of Congenital Anomalies: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). This program invites applications to sequence DNA samples from childhood cancer cohorts (and RNA samples from tumors) where a genetic basis is suspected but not yet identified, or where understanding recurring somatic mutations can address crucial questions in biology and therap…
As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First Program), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First Program supported genomic data generating centers. Applicants are encouraged to propose sequencing of existing pediatric cancer or congenital anomaly cohorts to elucidate the genetic contribution (somatic and/or germline) to childhood cancers, to investigate the genetic etiology of congenital anomalies, to study the molecular basis of the associations between congenital anomalies and increased cancer risk, or to expand the range of pediatric disorders included within the Kids First Data Resource. The program will accept applications that propose whole genome, exome, and transcriptome sequencing, as well as clinical-grade sequencing, long-read sequencing, proteomics, and epigenomic assays of tumor or affected tissue, when justified. Applicants are encouraged to propose cohorts to increase representation of existing Kids First Program projects. These data, and associated clinical and phenotypic data, will become part of the Kids First Data Resource Center for sharing with the research community. Funding Opportunity Number: PAR-27-071. Assistance Listing: 93.310. Funding Instrument: O. Category: HL.
The FY2026 COPS Hiring Program puts $157.5 million on the table to help local, state, tribal, and territorial agencies hire or rehire sworn officers — up to 75% of entry-level salary and benefits, capped at $125,000 per officer over three years, with a 25% local match. Here is how the cost-share math actually works, why the retention clause is the real obligation, who is eligible, how to win a competitive award, and why the July 23 Grants.gov deadline hides a second July 29 date most applicants miss.
Read articleFY2026 COPS Hiring Program offers up to $125,000 per officer over three years, covering 75% of entry-level salary and benefits, with a 25% local match. Two deadlines, a mandatory retention year, and a scoring formula that rewards fiscal need and community-policing plans. Here's how small and mid-size agencies actually win.
Read articleThe Department of Education's IES SBIR program is one of the most overlooked non-dilutive funding sources for education-technology startups. It funds prototypes at $250K and proven products at $1M with no equity taken. Here is how the FY2026 tracks work, what reviewers reward, and why the June 29 deadline is tighter than it looks.
Read article